Oncology

Latest News

Patients in the cemiplimab group had superior disease-free survival vs placebo. | Image credit: Medical Works - stock.adobe.com
Cemiplimab Improves Disease-Free Survival in High-Risk, Advanced CSCC

June 13th 2025

Cemiplimab improved disease-free survival in patients with high-risk cutaneous squamous cell carcinoma (CSCC) and performed well in patients with advanced CSCC in the real-world setting.

The approval covers use of pembrolizumab as a single agent in the neoadjuvant setting, followed by adjuvant treatment with pembrolizumab in combination with radiotherapy with or without cisplatin after surgery, and then continued as a single agent. | Image credit: wladimir1804-stock.adobe.com
FDA Approves Perioperative Pembrolizumab in Resectable HNSCC

June 13th 2025

FDA approval-Olivier Le Moal-stock.adobe.com.jpeg
Mitomycin Intravesical Solution Gains FDA Approval for Recurrent Low-Grade NMIBC

June 12th 2025

AJMC
Utilization and Costs Among Oncologists Participating in a Private Insurance Shared Savings Model

June 11th 2025

The new report suggests the C5a-C5aRq axis might be a useful target in combination with existing therapies for cutaneous squamous cell carcinoma. | Image credit: vladimircaribb - stock.adobe.com
C5aR1 Flagged as Biomarker in Cutaneous Squamous Cell Carcinoma

June 7th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

Podcast: This Week in Managed Care—Addressing Social Needs Impacting Health and Other Health News
November 24th 2018

Podcast: This Week in Managed Care—Addressing Social Needs Impacting Health and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.
This Week in Managed Care: November 23, 2018
November 23rd 2018

This Week in Managed Care: November 23, 2018

This week, the top managed care news included HHS Secretary Alex Azar hinting that the government may get more involved in addressing social needs impacting health; work rules in Arkansas cost thousands their Medicaid coverage; research finds a shorter course of hepatitis C treatment may be just as effective as the full course of treatment.
Beth Wittmer on Educating Patients on Neutropenia as a Side of Effect of Cancer Treatment
November 22nd 2018

Beth Wittmer on Educating Patients on Neutropenia as a Side of Effect of Cancer Treatment

As patients start chemotherapy to treat their cancer, they are educated on the side effects, particularly neutropenia, said Beth Wittmer, RN, OCN, manager of care management at Florida Cancer Specialists and Research Institute.
Dr Thorvardur Halfdanarson: Access Is a Big Management Challenge in NETs
November 20th 2018

Dr Thorvardur Halfdanarson: Access Is a Big Management Challenge in NETs

Thorvardur Halfdanarson, MD, associate professor of medicine and consultant in medical oncology, Mayo Clinic, outlines the biggest management challenges in neuroendocrine tumors (NETs).
Site Logo
November 17th 2018

AMA's McAneny Calls for Real-time Oncology Payment Model Led by Physicians

Mary Caffrey
In the keynote address at Patient-Centered Oncology Care® 2018, Barbara McAneny, MD, a New Mexico oncologist/hematologist and the current president of the American Medical Association (AMA), shared her diagnosis for the current crisis in US healthcare, as well as a prescription—a new real-time oncology payment model led by physicians.
Dr Brian Koffman Highlights the Benefits and Risks of CAR T Therapy
November 17th 2018

Dr Brian Koffman Highlights the Benefits and Risks of CAR T Therapy

Since chimeric antigen receptor (CAR) T-cell therapy is still in early development there are benefits and risks that eligible patients will have to weigh, including the durable response against the limited amount of data and toxic side effects, said Brian Koffman, MDCM, DCFP, DABFM, MS Ed, medical director, CLL Society.
FDA Gives Speedy Approval to Brentuximab for Peripheral T-Cell Lymphoma
November 17th 2018

FDA Gives Speedy Approval to Brentuximab for Peripheral T-Cell Lymphoma

Allison Inserro
The FDA announced Friday it expanded the approved use of brentuximab vedotin (Adcetris) in combination with chemotherapy for adult patients with certain types of peripheral T-cell lymphoma, using a new review process designed to increase efficiency.
Nivolumab Plus Azacitidine Increased Response Rates in Patients With Relapsed AML
November 16th 2018

Nivolumab Plus Azacitidine Increased Response Rates in Patients With Relapsed AML

David Bai, PharmD
The addition of nivolumab to azacitidine led to significantly better overall response rate and overall survival compared with previous hypomethylating agent-based regimens in patients with relapsed acute myeloid leukemia (AML), according to the results of a recent phase 2 study.
Site Logo
November 16th 2018

Keeping Ahead of the Curve in the Transition to Oncology Value-Based Payment

Christina Mattina
At a session of The American Journal of Managed Care®'s Patient-Centered Oncology Care® 2018 meeting, held November 16 in Philadelphia, panelists shared their views on the future of oncology value-based payment models and how they as payers and providers can help advance these models.
Dr Marcus Neubauer Discusses the Evolution of Care Teams in Oncology
November 16th 2018

Dr Marcus Neubauer Discusses the Evolution of Care Teams in Oncology

As practices shift to value-based care, they need truly coordinated care teams that discuss high-risk patients and identify ways to deliver care to them, said Marcus Neubauer, MD, chief medical officer, US Oncology.
The New Oncology Bundle Model: What We Know and Don't Know
November 15th 2018

The New Oncology Bundle Model: What We Know and Don't Know

Darcie Hurteau
CMS' announcement of a new mandatory oncology bundled payment model wasn't a surprise. It reinforces CMS' continued commitment to creating innovative ways of transforming care.
Site Logo
November 14th 2018

Erich Mounce Joins OneOncology as Chief Operating Officer

Former chief exeutive officer of the West Cancer Center brings over 3 decades of technology, operations, and care advancement to the OneOncology National Network.
Cancer Surpasses CVD as Leading Cause of Death in High-Income Counties
November 14th 2018

Cancer Surpasses CVD as Leading Cause of Death in High-Income Counties

Jaime Rosenberg
As a result of increased prevention and improved medical treatment of cardiovascular disease (CVD), and despite increasing rates of obesity and diabetes, cancer has gradually surpassed CVD as the leading cause of death in high-income counties. However, CVD is more likely to be the leading cause of death in low-income counties.
Cost Burden for Patients With Blood Cancers Eclipses the Burden in Other Cancers
November 13th 2018

Cost Burden for Patients With Blood Cancers Eclipses the Burden in Other Cancers

Laura Joszt, MA
Patients with blood cancers are burdened with higher costs than patients with other cancers, and spending in blood cancers does not return to precancer levels, according to a new study from the Leukemia & Lymphoma Society.
Nobel Prize Winner Dr James Allison on the Impact His Work Has Made
November 12th 2018

Nobel Prize Winner Dr James Allison on the Impact His Work Has Made

It has been good knowing that treatments he has had a hand in developing will give years of quality life to patients, where treatments only gave a few months before, explained James Allison, PhD, chair of the Department of Immunology, the Vivian L. Smith Distinguished Chair in Immunology, director of the Parker Institute for Cancer Research, executive director of the Immunotherapy Platform at MD Anderson Cancer Center, and 2018 Nobel Prize cowinner in Medicine.
Site Logo
November 9th 2018

Hospital Cancer Pain Management by Electronic Health Record–Based Automatic Screening

Jinyoung Shin, MD, PhD Hyeonyoung Ko, MD, MPH Jeong Ah Kim, BS Yun-Mi Song, MD, PhD Jin Seok Ahn, MD, PhD Seok Jin Nam, MD, PhD Jungkwon Lee, MD, PhD
A cancer pain control program for inpatients based on electronic health record–based automatic screening provided effective pain relief and achieved high satisfaction among patients and physicians.
Azar Announces Mandatory Oncology Payment Model Is Coming
November 8th 2018

Azar Announces Mandatory Oncology Payment Model Is Coming

Mary Caffrey Allison Inserro
The announcement is an about-face from earlier efforts that scrapped a cardiac care bundled payment program originally developed during the Obama administration.
Dr Thorvardur Halfdanarson on Diagnostics in NETs
November 8th 2018

Dr Thorvardur Halfdanarson on Diagnostics in NETs

Thorvardur Halfdanarson, MD, associate professor of medicine and consultant in medical oncology, Mayo Clinic, discusses improvements in diagnostics for neuroendocrine tumors, as well as what improvements are still needed.
Immunotherapy Improves Survival in Metastatic Melanoma
November 7th 2018

Immunotherapy Improves Survival in Metastatic Melanoma

David Bai, PharmD
The use of CTLA-4, PD-1, or a combination approach achieved high response rates and improved overall survival in patients with CDKN2A mutations with metastatic melanoma, based on the results of a study by Helgadottir et al.
Early Access to Daratumumab Confirms Safety in Relapsed/Refractory Multiple Myeloma
November 7th 2018

Early Access to Daratumumab Confirms Safety in Relapsed/Refractory Multiple Myeloma

Laura Joszt, MA
Daratumumab, a human CD38-directed monoclonal antibody, has been confirmed as safe in a population of heavily pretreated patients with multiple myeloma who received access to the treatment before the medication was commercially available, according to an early access treatment protocol study published in Cancer.
Hispanics Living With HIV at Increased Risk of HPV-Related Cancers
November 6th 2018

Hispanics Living With HIV at Increased Risk of HPV-Related Cancers

Jaime Rosenberg
Hispanics living with HIV are at an increased risk of developing cancers caused by the human papillomavirus (HPV) compared to the general Hispanic population, and among people living with HIV, Hispanics are more likely to be diagnosed with cervical and penile cancer.
Dr Scott Paulson: Role of Somatostatin Analogs, Biomarkers in Treatment of GEP-NETs
November 6th 2018

Dr Scott Paulson: Role of Somatostatin Analogs, Biomarkers in Treatment of GEP-NETs

Somatostatins have been the most game-changing drug in the treatment landscape of gastroenteropancreatic neuroendocrine tumors, explained Scott Paulson, MD, co-director of the Gastrointestinal Research Program for The US Oncology Network, medical director for the Neuroendocrine Research and Treatment Center at Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center.
Leukemia Survival Improved From 1995 to 2009, but Racial Gaps Increased for Some Types
November 2nd 2018

Leukemia Survival Improved From 1995 to 2009, but Racial Gaps Increased for Some Types

Laura Joszt, MA
While survival from leukemia improved among adults from 1995 to 2009, and the survival gap between sexes decreased, the racial gap did not, according to new research published in Cancer.
New Melanoma Guidelines Identify Recommended Treatments, Weigh In on Genetic Testing
November 1st 2018

New Melanoma Guidelines Identify Recommended Treatments, Weigh In on Genetic Testing

Laura Joszt, MA
New guidelines released by the American Academy of Dermatology will help physicians provide the best treatment for more than 1 million Americans living with melanoma, the deadliest form of skin cancer. The guidelines also highlight the importance of discussions between physicians and patients.
Site Logo
November 1st 2018

Learnings From Priority Health's Oncology Payment Reform Model

Surabhi Dangi-Garimella, PhD
To speak about the success and continued development of Priority Health's payment reform model in cancer care, John Fox, MD, medical director at Priority Health, joined Dennis Zoet, chief business development officer at Cancer and Hematology Centers of Western Michigan, on a panel at the Community Oncology Alliance Payer Exchange Summit.
Dr Heloisa Soares on Barriers to Achieving Positive Outcomes in NETs, What's in Store for the Future
November 1st 2018

Dr Heloisa Soares on Barriers to Achieving Positive Outcomes in NETs, What's in Store for the Future

Heloisa Soares, MD, assistant professor, University of New Mexico Cancer Center-Albuquerque, outlines current barriers to achieving positive outcomes in neuroendocrine tumors (NETs) and what's in store for the future.
Ted Okon on Policy Priorities for COA in 2019
November 1st 2018

Ted Okon on Policy Priorities for COA in 2019

I’ve seen one case recently where a patient received $172,000 of drugs that were totally wasted. So, we’re going to be looking at this, we’re going to be looking at these middlemen getting in the way of the patient and the physician making a decision about their therapy, explained Ted Okon, executive director of COA.
Dr Lalan Wilfong Provides an Overview of Key Learnings From the OCM
November 1st 2018

Dr Lalan Wilfong Provides an Overview of Key Learnings From the OCM

Looking at total cost of care is difficult and figuring out what the practice is responsible for and not responsible for can be very difficult to do, said Lalan Wilfong, MD, executive vice president of Quality Programs at Texas Oncology.
Bo Gamble Explains How COA Defines Value in Oncology
October 31st 2018

Bo Gamble Explains How COA Defines Value in Oncology

A patient has their own set of values, providers have their own set of values, and the people that pay for it have their own set of values. So, [we all need to] come together, explains Bo Gamble, Director Of Strategic Practice Initiatives at the Community Oncology Alliance.
Site Logo
October 31st 2018

Experts Discuss Regulatory, Cultural Roadblocks to Progress With Value-Based Agreements

Surabhi Dangi-Garimella, PhD
At the Community Oncology Alliance Payer Exchange Summit, healthcare policy experts from a government relations firm and from the pharmaceutical industry provided an update on the progress with value-based agreements and also discussed the challenges posed by the existing infrastructure and operational framework.
<1
...
353637383940414243
...
186>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo